ODT News and Press, Odonate Therapeutics Inc. From 02/23/21

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020. As ...

Today, we revisit Odonate Therapeutics for the first time since October 2018. The company's main drug candidate Tesetaxel is advancing in trials and should have a FDA decision date on the horizon. A full investment analysis on Odonate follows in the paragraphs. For further d...

Odonate has only one drug, an oral version of well-known chemo drugs called taxanes. Its Phase 3 trial was solid, but the market may have misunderstood the data. PDUFA in 2022 may be able to improve the stock's current low price. For further details see: Odonate: A Simpl...

Odonate is a small biotech attempting to win approval for Tesetaxel, a chemotherapy treatment indicated for treatment of HER2 negative metastatic breast cancer. The company's share price nose dived from $45 in June to $13 in September last year after management released results from a...

Insider buying decreased last week. Notable Insider Buys: IQVIA Holdings Inc., Odonate Therapeutics, Inc., Steel Partners Holdings L.P., OPKO Health, Inc., Fidelity National Financial, Inc. Notable Insider Sells: Walmart Inc., Elastic N.V., Facebook, Inc., Enphase Energy, Inc., Ma...

Tang Capital Partners reported 41.6% stake or 16.03M  share holding in Odonate Therapeutics (ODT).The percentage calculation is based upon 38,541,612 common shares outstanding as of November 30, 2020.Since September 1, 2020, the Tang Capital have expended $5.6M to purchase 386,666 c...

Insider buying decreased in a holiday shortened week. Notable Insider Buys: Odonate Therapeutics, Inc., Jack Henry & Associates, Inc., NetApp, Inc., Guidewire Software, Inc., First Internet Bancorp. Notable Insider Sells: Walmart Inc., Facebook, Inc., Lemonade, Inc., WW Intern...

Chairman and CEO of Odonate Therapeutics ([[ODT]] +10.8%) Kevin Tang bought 275,784 shares of ODT on December 23 at average price of $15.16 a share. For further details see: Odonate CEO buys $4.2M shares

Gainers: Avinger (AVGR) +71%, Neoleukin Therapeutics (NLTX) +33%, Ampio Pharmaceuticals (AMPE) +25%, Odonate Therapeutics (ODT) +14%, INmune Bio (INMB) +9%.Losers: Jaguar Health (JAGX) -29%, Ocugen (OCGN) -23%, Second Sight Medical Produc...

Gainers: [[HTOOW]] +18.7%. [[SIF]] +16.4%. [[GBS]] +11.9%. [[ODT]] +10.9%. [[LAZRW]] +10.2%.Losers: [[ALT]] -10.5%. [[BFIIW]] -5.8%. [[BLU]] -4.2%. [[SCPL]] -4.0%. [[CATB]] -3.4%. For further details see: HTOOW, SIF, ALT and CATB among after-hours movers